Nuvo Pharmaceuticals Inc NRIFF

Comment...

[consultant99]

The market reaction to the news release has been muted - so far. Presumably this is because investors do not have enough information upon which to judge how important this news is. Rock has provided some information but it would be so much more informative if the company used their corporate presentations to provide more meaningful updates.

For instance what kind of timelines might be expected before P2% achieves regulatory approval?
How long before Nuvo might expect to see an initial order for Russia?
The amount paid seems to have been consciously withheld from the PR - does that mean it was insignificant, or perhaps is being withheld so as to not disadvantage negotiations currently underway for other regions?

There will be some investors disappointed with the PR as it might suggest that any hopes for a buyout have been dashed now that ROW rights are being sold piecemeal rather than as a single package.

I had hoped to review the contract on SEDAR but it has not been posted - I did see the notice for the AGM however. It is May 11, 2017 with the record date for voting being March 29th.

I understand the court battle over generic manufacturing of P2% is close to wrapping up and hopefully that will provide further upside for the stock price.

Let's hope for a positive Phase III trial in Europe and perhaps more clariety around the ROW sales. Nuvo bought back the P2% rights for S. America, Central America, South Africa and Israel in Nov 2014 - surely the sale of these rights will be sooner rather than later.

I suppose we might have to wait for the AGM to get a lot more info but there is a much that could come out by then. I remain guardedly optimistic.